Liquid biopsy has long been seen as key to the future of cancer diagnostics, treatment and even potentially prevention. But now, startup Karius Inc. has staked out its claim as the first to bring cell-free DNA analysis, which is often used in oncology and prenatal liquid biopsy applications, into the clinic for infectious disease detection, identification and treatment guidance.
Campbell, Calif.-based startup Supira Medical Inc. scooped up $35 million in a series B financing led by Cormorant Asset Management. Also participating in the round were The Capital Partnership, 415 Capital, Amed Ventures and Shifamed Angels. The new capital is earmarked to advance the development and clinical evaluation of the company’s next-generation percutaneous ventricular assist device.
Redwood City, Calif.-based Q Bio Inc., which is offering a quantitative assessment of personal health, has come out of stealth mode, scooping up $40 million in a series B funding round led by Andreessen Horowitz. The funds are earmarked to improve its proprietary platform and technology to make its preventive health services faster, better and more affordable for all.
PARIS – Sensome SAS, of Palaiseau, France, has closed a second funding round, of $9 million, with its original French investors (Kurma Partners SA, Invest Partners SA, BNP Paribas Développement SA and the Paris-Saclay Seed Fund), now joined by the Japanese-based Asahi Intecc Co. Ltd.
IDbyDNA Inc., a San Francisco-based metagenomics technology company, scooped up $20 million in series B financing in a round led by Artis Ventures. Genesys Capital and others participated in the round. The company plans to use the money to accelerate uptake of its Explify software platform.
HONG KONG – South Korean med tech Olive Healthcare Inc. has attracted ₩8 billion (US$6.91 million) in series B funding. The Seoul-based company is focused on abdominal fat scanning and breast cancer diagnosis, using nonradiative and noninvasive near infrared (NIR) technology, artificial intelligence (AI) algorithms, and big data processing for a customized medical service.
HONG KONG – South Korean-based med-tech Lunit Inc., of Seoul, has secured ₩30 billion (US$25.6 million) in series C funding. Founded in 2013, the Korean company has raised $50 million so far. Lunit’s corporate value was evaluated at as much as ₩200 billion as of the fundraising.
Surgical robotics company Virtual Incision Corp., of Lincoln, Neb., has raised $20 million in a series B+ financing led by returning investor Bluestem Capital. The funds are earmarked for clinical and regulatory programs aimed at commercializing the company’s MIRA (miniaturized in vivo robotic assistant) surgical robotic platform.
HONG KONG – South Korean med-tech venture Recens Medical Inc. has secured ₩7 billion (US$6 million) in series B funding. Lb Investment Inc., Kb Securities Co. Ltd., Bnk Securities Co. Ltd., Hyundai Venture Investment Corp. and Lighthouse Combined Investment Co. Ltd. participated in the investment.
Medford, Mass.-based startup Sofregen Medical Inc. has picked up $8 million in a series B round led by Anzu Partners LLC. The money is earmarked for continued development of Sofregen’s silk protein-based technology and for commercialization of its U.S. FDA-cleared Silk Voice for people with vocal cord problems.